Skip to main content

Future Challenges and Opportunities in Online Prescription Drug Promotion Research Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".

Publication ,  Journal Article
Southwell, BG; Rupert, DJ
Published in: Int J Health Policy Manag
January 16, 2016

Despite increased availability of online promotional tools for prescription drug marketers, evidence on online prescription drug promotion is far from settled or conclusive. We highlight ways in which online prescription drug promotion is similar to conventional broadcast and print advertising and ways in which it differs. We also highlight five key areas for future research: branded drug website influence on consumer knowledge and behavior, interactive features on branded drug websites, mobile viewing of branded websites and mobile advertisements, online promotion and non-US audiences, and social media and medication decisions.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Health Policy Manag

DOI

EISSN

2322-5939

Publication Date

January 16, 2016

Volume

5

Issue

3

Start / End Page

211 / 213

Location

Iran

Related Subject Headings

  • Social Media
  • Research
  • Publications
  • Prescription Drugs
  • Humans
  • 4407 Policy and administration
  • 4206 Public health
  • 4203 Health services and systems
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Southwell, Brian G., and Douglas J. Rupert. “Future Challenges and Opportunities in Online Prescription Drug Promotion Research Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".Int J Health Policy Manag 5, no. 3 (January 16, 2016): 211–13. https://doi.org/10.15171/ijhpm.2016.05.
Southwell, Brian G., and Douglas J. Rupert. “Future Challenges and Opportunities in Online Prescription Drug Promotion Research Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".Int J Health Policy Manag, vol. 5, no. 3, Jan. 2016, pp. 211–13. Pubmed, doi:10.15171/ijhpm.2016.05.

Published In

Int J Health Policy Manag

DOI

EISSN

2322-5939

Publication Date

January 16, 2016

Volume

5

Issue

3

Start / End Page

211 / 213

Location

Iran

Related Subject Headings

  • Social Media
  • Research
  • Publications
  • Prescription Drugs
  • Humans
  • 4407 Policy and administration
  • 4206 Public health
  • 4203 Health services and systems